Press release article from our research archive:

Axcan Receives Canadian Approval for Helicide, a Single Capsule Triple Therapy for the Eradication of Helicobacter Pylori; TSX SYMBOL (Toronto Stock Exchange): AXP Nasdaq SYMBOL (Nasdaq National Market): AXCA.

Axcan Pharma Inc. ("Axcan" or the "Company") announced today that it received approval from the Therapeutic Products Directorate of Health Canada for HELICIDE, a patented single capsule triple therapy, for the eradication of Helicobacter pylori which is a bacterium now recognized as being the main cause of gastric and duodenal ulcers. Each HELICIDE capsule contains the equivalent of 40 mg of bismuth biskalcitrate (bismuth), 125 mg of metronidazole and 125 mg of tetracycline hydrochloride (tetracycline), and is administered in combination with a proton pump inhibitor.

"We are very pleased with this approval since our studies confirmed that HELICIDE is not only as effective ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!